What Has Been the Progress and Growth of the Acromegaly Market in Recent Years?
The acromegaly market has seen considerable growth due to a variety of factors.
• In recent times, there has been substantial growth in the acromegaly market size. This market is projected to expand from $2.15 billion in 2024 to $2.57 billion in 2025, with a compound annual growth rate (CAGR) of 19.6%.
Factors contributing to the growth during the historic period include an increased prevalence of acromegaly treatments, heightened awareness about acromegaly, government initiatives, and the demand for effective therapy options.
What Can Be Expected from the Acromegaly Market By 2029?
The acromegaly market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for Acromegaly is predicted to experience accelerated expansion in the upcoming years, reaching a staggering $4.92 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 17.6%.
This growth during the forecasted period is credited to increased funding in research and development for treating acromegaly, the upsurge in screening programs, elevated health expenditure, and the growing public interest in less invasive therapy options. Significant trends for the forecast period involve the creation of innovative avenues for acromegaly treatment, inception of specialized therapy for the disease, a robust pipeline of pharmaceuticals, progress in treatment alternatives, and sophistication in personalised medicine.
Which Key Drivers Are Propelling The Acromegaly Market's Growth?
The rise in hormonal diseases like diabetes is anticipated to boost the acromegaly market's expansion. Such diseases, also referred to as endocrine disorders, stem from malfunctions within the endocrine system. Among these disorders, diabetes is particularly widespread and consequential. Acromegaly, along with other endocrine disorders, can emerge from an excessive hormone production such as that of the growth hormone or cortisol. Due to high growth hormone levels impacting insulin synthesis, almost 50% of acromegaly patients may experience insulin resistance or have type 2 diabetes mellitus. In a case study, the Office for Health Improvement and Disparities in the UK reported in March 2024 that between March 2022 and March 2023, people suffering from type 1 diabetes who received all eight suggested care processes increased by 22%, while for type 2 diabetes, this number rose by 21%. Meanwhile, the percentage reaching HbA1c target levels jumped to 37.9%, constituting a record high as per the National Diabetes Audit (NDA). This escalation in cases of hormonal diseases is thereby fuelling the growth of the acromegaly market.
Driver effecting the Acromegaly Market: Increasing Genetic Defects
How Is The Acromegaly Market segmented?
The acromegaly market covered in this report is segmented –
1) By Type: Ectopic Acromegaly, Acromegaly Due To Growth Hormone
2) By Diagnosis: GH And IGF-I Measurement, Growth Hormone Suppression Test, Imaging, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By Treatment: Medication, Somatostatin analogues, Dopamine Agonists, Growth Hormone Antagonist, Surgery, Radiation, Other Treatments
5) By End Users: Hospitals, Specialty Clinics, Homecare, Other End Users
Subsegments:
1) By Ectopic Acromegaly: Tumor-Induced Ectopic Acromegaly, Non-Tumor-Induced Ectopic Acromegaly
2) By Acromegaly Due To Growth Hormone: Primary Growth Hormone Excess, Secondary Growth Hormone Excess
Pre-Book The Acromegaly Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Acromegaly Market?
Leading corporations in the acromegaly market are strategizing to innovate new products and solutions such as generic lanreotide, with the aim to amplify treatment alternatives and better patient outcomes. Generic lanreotide is essentially an unbranded version of the medication that is used to treat acromegaly and certain kinds of neuroendocrine tumours. It serves as a somatostatin analogue, curbing the secretion of growth hormone and broadening patient access to efficient treatment solutions. For example, Teva Pharmaceutical Industries Ltd., a generics-focused pharmaceutical firm based in Israel, became the first to launch a generic version of Sandostatin LAR Depot in America in October 2024. This injectable suspension, known as octreotide acetate, is prescribed for treating acromegaly and severe diarrhea related to carcinoid syndrome. This recent launch has expanded access to vital therapies for patients in need of such treatments.
Who Are the Key Players In The Acromegaly Market?
Major companies operating in the acromegaly market are:
• Pfizer Inc.
• Johnson & Johnson Private Limited
• Merck & Co Inc.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• AstraZeneca PLC
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH.
• Amgen Inc.
• Allergan Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Ipsen Pharma S.A.
• Hikma Pharmaceuticals PLC
• Lupin Ltd.
• Recordati S.p.A.
• Ionis Pharmaceuticals Inc.
• Amryt Pharma plc
• Strongbridge Biopharma PLC
• Aquestive Therapeutics Inc.
• Peptron Inc.
• Crinetics Pharmaceuticals
• Chiasma Inc.
What Is The Most Dominant Region In The Acromegaly Market?
North America was the largest region in the acromegaly market in 2024. The regions covered in acromegaly market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
